134 related articles for article (PubMed ID: 38889736)
1. Daratumumab maintenance in patients with myeloma.
Beksac M
Lancet Oncol; 2024 Jun; ():. PubMed ID: 38889736
[No Abstract] [Full Text] [Related]
2. Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
Mian H; Eisfeld C; Venner CP; Masih-Khan E; Kardjadj M; Jimenez-Zepeda VH; Khandanpour C; Lenz G; McCurdy A; Sebag M; Song K; LeBlanc R; White D; Stakiw J; Reiman A; Louzada M; Aslam M; Kotb R; Gul E; Reece D
Front Oncol; 2022; 12():826342. PubMed ID: 35251992
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Zweegman S; Caillon H; Caillot D; Avet-Loiseau H; Delforge M; Dejoie T; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Schiano de Colella JM; van de Donk NW; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Hua W; Wang J; Tuozzo A; de Boer C; Rowe M; Vanquickelberghe V; Carson R; Vermeulen J; Corre J; Sonneveld P;
Lancet Oncol; 2024 Jun; ():. PubMed ID: 38889735
[TBL] [Abstract][Full Text] [Related]
4. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
Ma Y; Xiao XB; Chen XL; Yuan SZ; Lu Y; Zhao SH; Chen JL; Shi GN; Wang YQ; Cheng NN; Feng P; Ding MS; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1016-1021. PubMed ID: 38503525
[No Abstract] [Full Text] [Related]
5. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab for the treatment of multiple myeloma.
Goldsmith SR; Foley N; Schroeder MA
Drugs Today (Barc); 2021 Oct; 57(10):591-605. PubMed ID: 34713868
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting.
Gordan LN; Marks SM; Xue M; Nagovski N; Lambert JH; Smith RE
Future Oncol; 2022 Jan; 18(3):301-309. PubMed ID: 34709061
[TBL] [Abstract][Full Text] [Related]
10. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
11. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Dinner S; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG
Lancet Haematol; 2023 Oct; 10(10):e825-e837. PubMed ID: 37708911
[TBL] [Abstract][Full Text] [Related]
12. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma.
Wang P; Jin SY
World J Clin Cases; 2023 Oct; 11(29):7091-7100. PubMed ID: 37946760
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
16. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
17. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
18. A rare case of daratumumab-associated encephalopathy in multiple myeloma.
Xiang J; Hong Z; Zhang Y; Chen J; Shen J; Zhu N
Immunotherapy; 2024 Apr; 16(7):447-452. PubMed ID: 38440862
[TBL] [Abstract][Full Text] [Related]
19. Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab.
Meng J; Zhao X; Jiang D; Liang C; Ji X; Dong M
J Oncol; 2022; 2022():9350211. PubMed ID: 36065307
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Abdallah AO; Mahmoudjafari Z; Ahmed N; Cui W; Shune L; McGuirk J; Mohan M; Mohyuddin GR; Afrough A; Alkharabsheh O; Atrash S
Eur J Haematol; 2023 Jun; 110(6):626-632. PubMed ID: 36752328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
